CG Oncology Stock Jumps 23.7% After Phase 3 PIVOT-006 Bladder Cancer Data

CG Oncology shares surged to $92 in premarket trading after Phase 3 data showed a 68% reduction in recurrence risk in non-muscle invasive bladder cancer. The result strengthens the case for cretostimogene as a potential post-surgery standard in a large untreated market.

CG Oncology stock surged 23.7% to $92 in premarket trading on November 16 after the company released topline Phase 3 results from its PIVOT-006 trial. The central number driving the move was a 68% reduction in recurrence risk for patients treated with cretostimogene grenadenorepvec after surgery, compared with surveillance alone.

The study hit its primary endpoint with a hazard ratio of 0.32, a 95% confidence interval of 0.23 to 0.45, and a p-value below 0.0001. For investors, the magnitude of benefit matters as much as the statistical success: the result appears to have exceeded the level many had modeled before the readout.

The rally is notable because it arrived in a weak broader market for growth and biotech shares. That points to a stock-specific repricing tied to one event: randomized late-stage evidence that CG Oncology may have opened a larger commercial path for its only clinical asset.

Key Facts

  • CG Oncology shares indicated $92 in premarket trading on November 16, up 23.7% and above the prior 52-week high of $80.97.
  • PIVOT-006 enrolled 367 patients across 90 sites in the U.S. and Canada, with median follow-up of 17 months as of the October 26, 2026 cutoff.
  • Cretostimogene cut recurrence risk by 68% versus surveillance, with a hazard ratio of 0.32 and p-value below 0.0001.
  • The company reported no Grade 3 or higher treatment-related adverse events and no treatment-related discontinuations in the Phase 3 study.
  • CG Oncology ended the third quarter with $984.5 million in cash, cash equivalents and marketable securities, which it expects to fund operations through 2029.

CG Oncology PIVOT-006 Trial Results

The PIVOT-006 readout is important because it addresses intermediate-risk and high-grade Ta non-muscle invasive bladder cancer, an area with limited approved post-surgery treatment options. All patients first underwent tumor removal through transurethral resection, then either received intravesical cretostimogene or entered surveillance, the current standard approach.

The scale of benefit is what is driving the market response. A hazard ratio of 0.32 implies that recurrence events occurred far less often in the treatment arm during follow-up. In practical terms, fewer recurrences can mean fewer repeat procedures, fewer cystoscopies, and lower cumulative treatment burden for patients whose disease often returns after resection.

The result also matters strategically. CG Oncology had largely been viewed as a company built around BCG-unresponsive disease, where its first biologics license application is planned. PIVOT-006 broadens that story by adding randomized registrational evidence in an earlier and potentially larger setting, which could materially expand the addressable market if regulators agree with the filing strategy.

“A 68% reduction in recurrence risk moves cretostimogene from a niche bladder cancer therapy toward a potential backbone treatment across bladder-sparing NMIBC care.”

Why the data changed the valuation

Late-stage biotech stocks often rise on positive data, but the size of this move suggests investors are also revising commercial assumptions. Before the readout, the market appeared to expect a more modest recurrence benefit. Delivering well above that implied threshold can increase both the probability of approval and the potential revenue opportunity.

Safety helped reinforce the efficacy case. In intermediate-risk disease, physicians are generally cautious about exposing patients to therapies with meaningful toxicity because the disease is recurrent but not always rapidly life-threatening. A clean tolerability profile improves the odds of physician adoption, payer support, and a broader eventual label.

Implications for Investors

For shareholders, the near-term setup has improved, but the story remains event-driven. The prior 52-week high near $80.97 may now act as a technical reference point after the breakout. Investors will also watch the December 2 Society of Urologic Oncology presentation for subgroup data, recurrence curves, and more detail on durability through 17 months.

Regulatory timing is still a factor. The company said its first BLA in BCG-unresponsive disease is now expected to be completed before the end of March 2027, compared with prior guidance for the fourth quarter of 2026, as it seeks to broaden the label. A second BLA for intermediate-risk disease is expected in the second quarter of 2027. That means revenue remains several quarters away, and execution risk has not disappeared.

Balance sheet strength reduces one major biotech risk. CG Oncology reported $984.5 million in cash and marketable securities at September 30, against a quarterly net loss of $56.9 million and quarterly revenue of $1.6 million. That funding runway gives the company flexibility to complete filings and prepare for launch without immediate pressure to raise capital, although investors will still monitor dilution risk after a sharp share-price increase.

Competition is another watch point. The bladder cancer market already includes approved products in the BCG-unresponsive setting, but the post-surgery intermediate-risk segment remains less crowded. If cretostimogene ultimately secures approval with randomized Phase 3 support, CG Oncology could enter that niche with a meaningful first-mover advantage.

The next phase for the stock will depend on whether detailed December data confirm durability, whether filing timelines hold, and how investors value a single-asset company with a potentially much larger commercial footprint. For now, PIVOT-006 has shifted the debate from whether the drug works to how quickly CG Oncology can turn clinical momentum into approvals and market share.

Ultima Markets